| RYMCX | VSMAX | RYMCX / VSMAX | |
| Total Expense Ratio | 2.24 | 0.05 | 4,480% |
| Annual Report Gross Expense Ratio | 2.49 | 0.05 | 4,980% |
| Fund Existence | 28 years | 26 years | - |
| Gain YTD | 33.165 | 14.588 | 227% |
| Front Load | N/A | N/A | - |
| Min. Initial Investment | 2000 | 3000 | 67% |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 390M | 189B | 0% |
| Annual Yield % from dividends | 0.00 | 1.21 | - |
| Returns for 1 year | 30.04 | 22.58 | 133% |
| Returns for 3 years | 25.84 | 43.42 | 60% |
| Returns for 5 years | -11.60 | 35.11 | -33% |
| Returns for 10 years | 13.24 | 155.96 | 8% |
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| BQLCX | 23.42 | 0.17 | +0.73% |
| Bright Rock Quality Large Cap Instl | |||
| GSPQX | 20.02 | 0.12 | +0.60% |
| Goldman Sachs US Eq Div and Premium C | |||
| GSIYX | 24.29 | N/A | N/A |
| Goldman Sachs GQG Ptnrs Intl Opps R6 | |||
| CCWIX | 21.73 | -0.15 | -0.69% |
| Baird Chautauqua International Gr Instl | |||
| RYOAX | 66.89 | -1.55 | -2.26% |
| Rydex Biotechnology H | |||